Mimicking dominant negative inhibition of prion replication through structure-based drug design.
about
Doppel-induced cerebellar degeneration in transgenic mice2-Aminothiazoles as therapeutic leads for prion diseasesHot spots in prion protein for pathogenic conversionTrans-dominant inhibition of prion propagation in vitro is not mediated by an accessory cofactorStructure-Based Drug Discovery for Prion Disease Using a Novel Binding SimulationThe dominant-negative effect of the Q218K variant of the prion protein does not require protein X.Mapping the early steps in the pH-induced conformational conversion of the prion protein.Systematic identification of antiprion drugs by high-throughput screening based on scanning for intensely fluorescent targets.Isolation and characterization of a polymerized prion protein.Potent inhibition of scrapie prion replication in cultured cells by bis-acridines.Acridine and phenothiazine derivatives as pharmacotherapeutics for prion diseaseDominant-negative inhibition of prion replication in transgenic mice.Characterizing antiprion compounds based on their binding properties to prion proteins: implications as medical chaperones.Therapeutic strategies for human amyloid diseases.The transmissible spongiform encephalopathies: pathogenic mechanisms and strategies for therapeutic intervention.Ex vivo propagation of infectious sheep scrapie agent in heterologous epithelial cells expressing ovine prion proteinA survey of antiprion compounds reveals the prevalence of non-PrP molecular targets.Emerging therapeutic agents for transmissible spongiform encephalopathies: a review.Prion diseases: from molecular biology to intervention strategies.Phosphorothioate oligonucleotides reduce PrP levels and prion infectivity in cultured cells.Recent advances in prion chemotherapeutics.Multi-component synthesis of 2-amino-6-(alkyllthio)pyridine-3,5-dicarbonitriles using Zn(II) and Cd(II) metal-organic frameworks (MOFs) under solvent-free conditions.NMR structure and CD titration with metal cations of human prion alpha2-helix-related peptides.Chimeric elk/mouse prion proteins in transgenic mice.In silico strategies on prion pathogenic conversion and inhibition from PrPC -PrPSc.Exploring Anti-Prion Glyco-Based and Aromatic Scaffolds: A Chemical Strategy for the Quality of Life.Inhibition of PrPSc formation by lentiviral gene transfer of PrP containing dominant negative mutations.Anti-PrP antibodies block PrPSc replication in prion-infected cell cultures by accelerating PrPC degradation.Glycan-controlled epitopes of prion protein include a major determinant of susceptibility to sheep scrapie.Cyclodextrins inhibit replication of scrapie prion protein in cell culture.Cellular factors implicated in prion replication.Prediction of antiprion activity of therapeutic agents with structure-activity models.Benign by design: catalyst-free in-water, on-water green chemical methodologies in organic synthesis.Cloning and paratope analysis of an antibody fragment, a rational approach for the design of a PAI-1 inhibitor.Antibodies inhibit prion propagation and clear cell cultures of prion infectivity.Unraveling the key to the resistance of canids to prion diseases.Targeting of Disordered Proteins by Small Molecules in Neurodegenerative Diseases.Pharmacological Agents Targeting the Cellular Prion Protein.Inhibition of interactions and interconversions of prion protein isoforms by peptide fragments from the C-terminal folded domain.Polyclonal anti-PrP auto-antibodies induced with dimeric PrP interfere efficiently with PrPSc propagation in prion-infected cells.
P2860
Q24555049-B7ECE8CA-A6A3-44CC-B42A-B806E84CDD03Q24618566-ED736034-1191-4D9F-876D-2A93756740C2Q24670553-439B4D62-054B-4235-A206-F6FC4B437A9AQ27316451-5B955F3E-ABF8-4F68-99BF-6DD70539ABDDQ28831416-2558AA5A-B12E-4C56-B2D0-BBB5B46ED007Q30493219-876D46CC-0D52-4E33-A671-0B28CBF61AE1Q30638581-BAF3183B-82BB-47D3-8122-4FF89F1438ADQ30784753-FDCECD42-8B4E-42A0-B1B7-94336D170A5BQ31050944-69959CFA-E6A3-4B30-965B-C6A329EAAB34Q31134598-90C52CAC-5BE4-4E66-ADBC-7541F9AE0E95Q33933969-AE7D27FC-608E-4D6C-97A9-D0D347ADE068Q34191612-849420B2-523B-4DB8-8F3B-793CF9389B9CQ34307103-C87B6960-946A-42AD-B535-BC0253B913A1Q34743288-B31E4809-EB9B-4DF9-B0E9-8C0D36563EBEQ35050425-F29E6901-94F7-4BD0-B85B-3F94C59B3A99Q35053001-8F394137-093E-4DA1-A7C3-2B0E0FD4F905Q35145020-519E7A55-FE55-4FC2-A283-747B2FC417DDQ35591287-E0004E57-9CD8-4F01-A630-2A36A542A04EQ35602374-96F4FB9D-9966-4425-B596-69D07F915D86Q35844090-BB612483-4B7D-4E6B-909F-931D46C2B9C8Q35944199-BD8730BE-4073-440A-B33E-4482AB2B5A96Q36246879-DA320337-BC94-4B7D-BA37-3604B35BF2C3Q36409852-9B3FA115-5F4A-4547-9CB2-930E58FAE89EQ37006731-A4B6FC80-DEED-4C6A-9EC9-526996E5E7F4Q39101358-352704A6-730F-4DAF-BE64-EB9BC6F86FA7Q39326827-4065CB34-D771-4D8E-83A4-7ABFC0F7DEA6Q39692874-6B0AC0F9-3F3C-45E1-8593-156188D403EEQ39719132-E50FB516-8F9F-4BAD-BCD2-1AC1C3BCE933Q39755869-8C0161DE-0C7B-4D13-B4DB-33D234308C15Q40093984-11B95A66-0999-4756-99A3-47F95635A335Q41853767-48BBBC75-8849-4B2B-8A27-A5B61B89A448Q43966734-B2E1B497-85FB-490B-942C-943481FD1532Q44767766-5DFCD51F-3E22-4302-8DEA-DA3C24B45DCAQ44783383-9F22A3E5-D769-4EC8-9957-6D7650DEC923Q46161882-F7048154-4995-42C7-BAA6-48CA4AA94E42Q46262712-214D049E-8191-409D-B3F2-C9E957A9679CQ47720283-C4CB035A-17A7-4C05-8A2A-65DE0F7D3630Q52666286-47D6551A-4C2E-441C-9A31-B86C26A38711Q54014606-41CE5959-A459-4CE8-8AC0-8B14CD525238Q54528615-A3EB5B28-CB55-4392-84C3-0231C02663E5
P2860
Mimicking dominant negative inhibition of prion replication through structure-based drug design.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Mimicking dominant negative in ...... h structure-based drug design.
@ast
Mimicking dominant negative in ...... h structure-based drug design.
@en
type
label
Mimicking dominant negative in ...... h structure-based drug design.
@ast
Mimicking dominant negative in ...... h structure-based drug design.
@en
prefLabel
Mimicking dominant negative in ...... h structure-based drug design.
@ast
Mimicking dominant negative in ...... h structure-based drug design.
@en
P2093
P2860
P356
P1476
Mimicking dominant negative in ...... h structure-based drug design.
@en
P2093
P2860
P304
P356
10.1073/PNAS.97.11.6073
P407
P577
2000-05-01T00:00:00Z